Background
==========

Rheumatoid arthritis (RA) is a common inflammatory disorder with complex etiology. Although the causes of RA are still unclear, it is believed to be attributed to both genetic and environmental factors. During the last few decades, many new genetic regions have been identified to associate with RA. Remmers et al. \[[@B1]\] showed that *STAT4*was an important genetic marker for both RA and systemic lupus erythematosus susceptibility. Kurreeman et al. \[[@B2]\] applied the candidate gene approach to the *TRAF1-C5*region and found a polymorphism that increased the susceptibility and severity of RA. Plenge et al. \[[@B3]\] studied 14 candidate genes and found significant associations between RA and *PTPN22*, *CTLA4*, and *PADI4*. Although many genes have shown suggestive connections with RA, only *HLADRB1*and *PTPN22*have been confirmed to increase the genetic risk of developing RA \[[@B4]\]. An explanation for the large number of identified genes might lie in the existence of gene-gene interactions, which, while helpful in identifying and compiling genes, also made the analysis much more complicated.

The traditional approaches used in association studies analyze markers marginally one at a time. As a result, valuable information on the interactions of genes was lost. Zheng et al. \[[@B5]\] proposed an association measure, the genotype-trait distortion (GTD), for evaluating association information on unphased multilocus genotypes from case-control data. GTD was shown to be able to capture interactions between markers that were associated with the disease \[[@B5]\].

Many current association studies are based on dense single-nucleotide polymorphism (SNP) data, with multiple SNPs corresponding to one gene. SNP-based methods are used to identify and replicate the most significant SNP. Without considering the dependence and functional relevance among SNPs within the same gene, most SNP-based association analysis may lead to false-negative results. As marker density increases, one could consider a gene-based analysis that offers a number of advantages, for instance, taking into account possible multiple disease-associated functional variants within a gene and overcoming the dependence among SNPs due to close proximity. In this study, we used the GTD score and applied a gene-based analysis on two sets of RA candidate genes from the North American Rheumatoid Arthritis Consortium (NARAC) data as part of Problem 1 of the Genetic Analysis Workshop 16 (GAW16).

Methods
=======

Gene Set I
----------

The Illumina data set of GAW16 Problem 1 consists of 545,080 SNPs genotyped on 868 RA cases and 1194 unaffected controls from NARAC. In our study, 531 SNPs from 27 candidate gene regions were considered (Table [1](#T1){ref-type="table"}). The SNPs numbers and locations were identified by using the SNP mapping information from the National Cancer Institute\'s Cancer Genetic Markers of Susceptibility (CGEMS) initiative \[[@B6]\]. We included all related SNPs within each gene in the analysis. These 27 candidate genes were selected based on our search of the RA literatures. Among these 27 candidate genes, *HLADRB1*and *PTPN22*have been widely studied and confirmed to be associated with RA risk. Some of the candidate genes (*PADI4*, *FCRL3*, *FCGR3*, *TNFRSF1B*, *STAT4*, *CTLA4*, *IL4*, *HAVCR1*, *TNF*, *MICA*, *NFKBIL1*, *OLIG3*-*TNFAIP3*, *TRAF1*-*C5*, *MHC2TA*, and *MIF*) have been replicated in different populations. A few candidate genes (*IL10*, *BTLA*, *IL1B*, *ITGAV*, *SLC22A4*, *IL3*, *VEGF*, and *RUNX1*) showed positive association in individual studies but have not been replicated in other independent data sets. In addition, we also included *DLG5*and *CARD15*because they were found to be associated with several autoimmune diseases. SNPs with missing data were imputed by fastPhase \[[@B7]\].

###### 

RA candidate genes

  Gene                Gene Set I   Gene Set II   Locus          SNPs
  ------------------- ------------ ------------- -------------- ------
  *PTPN22*            Yes          Yes           1p13           12
  *PADI4*             Yes          Yes           1p36.13        18
  *FCRL3*             Yes          No            1q21.2-q22     8
  *FCGR3*             Yes          Yes           1q23           4
  *IL10*              Yes          No            1q31-q32       16
  *TNFRSF1B*          Yes          Yes           1p36.3-p36.2   21
  *IL1B*              Yes          Yes           2q14           7
  *ITGAV*             Yes          Yes           2q31           16
  *STAT4*             Yes          Yes           2q32.2-q32.3   30
  *CTLA4*             Yes          Yes           2q33           5
  *BTLA*              Yes          Yes           3q13.2         6
  *SLC22A4*           Yes          Yes           5q31           19
  *IL13*              No           Yes           5q31           6
  *IL3*               Yes          Yes           5q31.1         3
  *IL4*               Yes          No            5q31.1         7
  *HAVCR1*            Yes          No            5q33.2         15
  *VEGF*              Yes          Yes           6p12           12
  *HLADRB1*           Yes          Yes           6p21.3         5
  *MICA*              Yes          No            6p21.3         32
  *HLA-A*             No           Yes           6p21.3         6
  *HLA-B*             No           Yes           6p21.3         24
  *HLA-C*             No           Yes           6p21.3         29
  *LTA*               No           Yes           6p21.3         11
  *NFKBIL1*           Yes          Yes           6p21.3         19
  *TNF*               Yes          Yes           6p21.3         10
  *OLIG3 - TNFAIP3*   Yes          No            6q23           76
  *IL6*               No           Yes           7q21           14
  *TRAF1-C5*          Yes          Yes           9q33-q34       31
  *DLG5*              Yes          No            10q23          17
  *MS4A1*             No           Yes           11q31          13
  *MHC2TA*            Yes          No            16p13          12
  *CARD15*            Yes          No            16q12          11
  *RUNX1*             Yes          No            21q22.3        104
  *MIF*               Yes          Yes           22q11.2        15

Gene Set II
-----------

After the gene × gene interaction group discussion during the GAW16 conference, 24 candidate genes were selected for further analysis based on the contributors\' findings (Table [1](#T1){ref-type="table"}), 17 of which were considered in our original analysis (Gene Set I). The seven added genes are *IL13*, *HLA-A*, *HLA-B*, *HLA-C*, *LTA*, *IL6*, and *MS4A1*, which were identified in other contributors\' studies. In other words, we applied our method to re-analyze the same RA data with different candidate genes from Gene Set I.

Methods
=======

Given *k*SNP makers, there are 3^*k*^possible unphased genotypes. We can use the following GTD statistic defined on the sum of squared difference between genotypes\' relative frequency among the cases and controls to measure the joint effects of these *k*SNPs on the disease status, i.e.,

The statistic *ν*and its variations have been applied successfully in a number of studies \[[@B5],[@B8]-[@B10]\]. Specifically, GTD was applied to a candidate gene study of RA during GAW15 \[[@B10]\] and identified significant higher-order interactions that were missed by other methods such as the multifactor dimensionality reduction (MDR) \[[@B10]-[@B12]\].

To identify significant interactions, we applied 1000 permutations of the case-control outcomes as in Lo et al. \[[@B13]\]. Based on *ν*, we applied the following gene-based analysis procedures developed by Lo et al. \[[@B13]\] to analyze our data sets:

1\. Suppose that there are *l*genes with *m*~*i*~SNPs in gene *i*and the total number of SNPs is *m*(). For example, *l*= 27 and *m*= 531 in Gene Set I. We calculated for SNP *d*of gene *i*(*k*= 1) and took an average over the *m*~*i*~SNPs for each gene *i*, which resulted in *l*averages of the marginal effect of each gene.

2\. We randomly permuted the labels of case (*Y*= 1) and control (*Y*= 0) and repeated Step 1 on the permuted data while the original dependence among SNPs in each gene were retained.

3\. To find the pair-wise interaction among the *l*genes, we examined *l*× (*l*-1)/2 gene pairs. We first calculated the interaction genotype statistics for *m*× (*m*-1)/2 SNP pairs (*k*= 2) and defined the SNP-wise interaction as the ratio of incremental interaction versus the maximum of the two marginal effects as in Eq. (2) where \"∨ \" stands for maximum of the two values.

Second, we defined the interaction between genes *i*and *j*as the average of all SNP-wise ratios in Eq. (3). The ratio is termed as the \"mean interaction ratio,\" *Mean-ratio*, or *R*statistic. In addition, we also defined the gene-level \"average maximum marginal,\" or *M*, as in Eq. (4).

4\. Applying the calculation outlined in Step 3 on the permuted data sets, we obtained a set of *l*× (*l*-1)/2 values {} for each permutation *p*. The *Mean-ratio curve method*of the following was applied to identify significant gene-pairs. All 1000 × *l*× (*l*-1)/2 points were put on the (*M, R*) plane and separated into 100 bins according to the *M*values. Each bin had 10 × *l*× (*l*-1)/2 points. For each bin, we identified the 99 percentile of the *R*statistics (*R*\*) that fell within this bin. By fitting a smoothing spline between the mid-values of each bin (*M*\*) and *R*\*, we constructed the 99% *R*threshold curve conditioning on *M*. We identified gene-pairs with observed *R*statistics above the threshold curve as significant.

5\. In addition to the mean ratio *R*, we used another measure of interaction, the *Quantile-ratio*statistic. The *Q*statistic is calculated as the 90^th^or 95^th^-quantile of the SNP-wise ratios formed by the *m*~*i*~*m*~*j*~SNP pairs. Significant *Q*~*ij*~values were identified by the *curve*method.

6\. An alternative way to evaluate the statistical significance is the *Rank*method. Similar to Step 4, we have 10 × *l*× (*l*-1)/2 points in each bin. The values of *R*in each bin are ranked from 1 to 10 × *l*× (*l*-1)/2. For each gene pair, the observed *R*value received such a rank value *T*, and the *R*value from permutation *p*received a rank value *T*^(*p*)^. The *p*-value of the gene-pair is then the proportion of *T*^(*p*)^≥ *T*. In this study a significance level of 0.01 is used. The same procedure can also be applied to the *Q*statistics calculated in Step 5.

Results
=======

From the average maximum marginal statistics, we observed that all *HLADRB1*-related gene pairs have the strongest *M*values. We applied both *Mean-ratio*and *Quantile-ratio*methods to capture the interactions. Thirteen interactions are significant at (*p*\< 0.01) by the *Rank*method. Seven interactions were identified by the quantile method at 90^th^and 95^th^level. One interaction (*ITGAV*and *VEGF*) was identified by the 90^th^-*Quantile Rank*method. The *Curve*method identified 10 interactions, all of which were overlapping with that of the *Rank*method. Table [2](#T2){ref-type="table"} shows the detailed selection results. In Figure [1](#F1){ref-type="fig"}, we reported the 14 significant gene-gene interactions from Gene Set I (3.51 significant interactions expected by chance) using red lines.

###### 

Selected interactions by different proposed procedures (*p*-value \< 0.01)

  Curve method     Rank method                                                                
  ---------------- ---------------- ---------------- -------------------- ------------------- ----------------
  *IL3 BTLA*       *IL3 BTLA*       *IL3 BTLA*       *IL3 BTLA*           *IL3 MIF*^a^        *IL3 BTLA*
  *IL3 MIF*        *IL3 MIF*        *IL3 MIF*        *IL3 MIF*            *IL3 PADI4*         *IL3 MIF*
  *IL3 PADI4*      *IL3 PADI4*      *IL3 PADI4*      *IL3 PADI4*          *IL3 TRAF1-C5*^a^   *IL3 PADI4*
  *IL3 SLC22A4*    *IL3 TRAF1-C5*   *IL3 TRAF1-C5*   *IL3 SLC22A4*        *ITGAV VEGF*        *MIF BTLA*
  *IL3 TNFRSF1B*   *MIF BTLA*       *MIF BTLA*       *IL3 TNFRSF1B*       *MIF BTLA*^a^       *MIF FCGR3A*
  *IL3 TRAF1-C5*   *MIF FCGR3A*                      *IL3 TRAF1-C5*       *MIF FCGR3A*^a^     *MIF TRAF1-C5*
  *MIF BTLA*       *MIF TRAF1-C5*                    *MIF BTLA*           *MIF TRAF1-C5*^a^   
  *MIF FCGR3A*     *FCGR3A*                          *MIF FCGR3A*                             
  *MIF ITGAV*      *TRAF1-C5*^a^                     *MIF HLA-B*^a^                           
  *MIF TRAF1-C5*                                     *MIF ITGAV*                              
  *MIF CTLA4*^a^                                     *MIF TNFRSF1B*^a^                        
                                                     *MIF TRAF1-C5*                           
                                                     *MIF VEGF*                               
                                                     *NFKBIL1 HLA-B*^a^                       
                                                     *NFKBIL1 VEGF*                           
                                                     *NFKBIL1 TNF*                            
                                                     *VEGF IL6*^a^                            
                                                     *VEGF HLA-B*^a^                          
                                                     *HLA-A HLA-B*^a^                         
                                                     *HLA-B HLA-C*^a^                         

^a^Significant interactions only identified in Gene Set II

![**Association network with significant interactions identified**. All significant interactions identified for Gene Set II are plotted. Interactions in red were also identified in Gene Set I. Different line widths indicate interactions identified by different numbers of proposed procedures.](1753-6561-3-S7-S75-1){#F1}

For Gene Set II (2.76 significant interactions expected by chance), in addition to the interactions identified for Gene Set I (Table [2](#T2){ref-type="table"}), another seven interactions were found to be significant by the *Mean-ratio Rank*method and two additional interactions were found significant by the *Curve*method. Figure [1](#F1){ref-type="fig"} displays the extended networks with these interactions. As seen in Figure [1](#F1){ref-type="fig"}, *MIF*seems to be a \"hub\" in the association network with nine significant interactions. In addition, *IL3*, *VEGF*, and *HLA-B*also have at least five significant interactions.

Morand et al. \[[@B14]\] suggested that *MIF*is a pivotal mediator of RA. In addition, it has been implicated in many roles such as leukocyte recruitment, activation, and the production of pro-inflammatory cytokines. All of the roles contributed to the pathology of RA and showed the importance of MIF. Many interactions identified in our study have been previously discussed in the literature. It has been demonstrated that serum and synovial fluid levels of *MIF*were well correlated with the *VEGF*levels in patients with RA \[[@B15]\]. Nakahara et al. \[[@B16]\] indicated that *IL-6*blockade directly suppressed *VEGF*production in synovial fibroblasts and may consequently reduce serum *VEGF*levels in patients with RA. Kiriakidis et al. \[[@B17]\] also showed that *VEGF*production in human macrophages was NF-*κ*B-dependent, which agreed with our finding of interaction between *VEGF*and *NFKBIL1*. *VEGF*may be directly involved in the activation of RA monocytes and synoviocytes, producing *TNF*and *IL-6*via a receptor-coupling event \[[@B18]\]. As noted in Yoo et al. \[[@B18]\], this may imply a direct interaction between *VEGF*and *IL-6*or an indirect interaction between *VEGF*and *TNF*via *NFKBIL1*, also found in our results. Onodera et al. \[[@B19]\] demonstrated that *MIF*enhanced NFKB binding activities of the nuclear extracts from RA synovial fibroblasts. The *NFKBIL1*, a divergent member of I-*κ*-B proteins that is an inhibitor for NFKB complex, may have potential interaction between *MIF*and *NFKBIL1*. In Figure [1](#F1){ref-type="fig"}, we showed that the indirect connection between *MIF*and *NFKBIL1*via *VEGF*. Furthermore, the relation between *TNF*and NFKB-dependent signaling pathway of RA patients was discussed by Youn et al. \[[@B20]\].

Conclusion
==========

In this paper, many relevant candidate regions reported in the literature were chosen for a more detailed analysis. We applied a recently developed method by Lo et al. \[[@B13]\] to identify potential gene-gene interactions that are associated with the susceptibility of RA. First, we found a strong marginal signal between *HLADRB1*and RA. In addition, the *Rank*and the *Curve*methods based on 1000 permutations identified a number of gene-pairs that are significantly associated with RA, many of which were previously reported in the literature. The association network constructed in our paper may offer additional evidence and insight on gene-gene interactions in the development of RA. Additional experiments and independent data are required to confirm our findings.
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